ReviewApoptosis : an international journal on programmed cell death2010
Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease.
Review in Apoptosis : an international journal on programmed cell death, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 73 citations in OpenAlex.
- Targeting efferocytosis with carbonized polymer dots from a natural anti-inflammatory drug to alleviate excessive inflammatory responses in the acute phase of myocardial infarction.Materials today. Bio · 2026Article
- The IL-4/IL-4R/STAT6 signaling axis regulates macrophage efferocytosis in osteoarthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Milk fat globule EGF and factor V/VIII domain containing (MFGE8) as a novel player in equine endometrial fibrosis.Scientific reports · 2026Article
- Efferocytosis in myocardial infarction: the regulatory core from inflammation resolution to cardiac repair.Frontiers in immunology · 2026Review
- The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis.Science signaling · 2025Article
- Efferocytosis in atherosclerosis.Nature reviews. Cardiology · 2024Review
- Macrophage-enriched Sectm1a promotes efficient efferocytosis to attenuate ischemia/reperfusion-induced cardiac injury.JCI insight · 2024Article
- The dance of macrophage death: the interplay between the inevitable and the microenvironment.Frontiers in immunology · 2024Review
- Efferocytosis by macrophages in physiological and pathological conditions: regulatory pathways and molecular mechanisms.Frontiers in immunology · 2024Review
- Role of the pioneer transcription factor GATA2 in health and disease.Journal of molecular medicine (Berlin, Germany) · 2023Review
- HOXA1 participates in VSMC-to-macrophage-like cell transformation via regulation of NF-κB p65 and KLF4: a potential mechanism of atherosclerosis pathogenesis.Molecular medicine (Cambridge, Mass.) · 2023Article
- Defective efferocytosis of vascular cells in heart disease.Frontiers in cardiovascular medicine · 2022Review
- Advances in Anti-metabolic Disease Treatments Targeting CD47.Current pharmaceutical design · 2022Review
- Different types of cell death in vascular diseases.Molecular biology reports · 2021Review
- Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease.Pathogens (Basel, Switzerland) · 2021Review
- The clearance of dead cells by efferocytosis.Nature reviews. Molecular cell biology · 2020Review
- Efferocytic Defects in Early Atherosclerosis Are Driven by GATA2 Overexpression in Macrophages.Frontiers in immunology · 2020Article
- Mechanism of Enhanced MerTK-Dependent Macrophage Efferocytosis by Extracellular Vesicles.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Long Noncoding Competing Endogenous RNA Networks in Age-Associated Cardiovascular Diseases.International journal of molecular sciences · 2019Review
- Quantification of Efferocytosis by Single-cell Fluorescence Microscopy.Journal of visualized experiments : JoVE · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Recent evidence in humans indicate that defective phagocytic clearance of dying cells is linked to progression of advanced atherosclerotic lesions, the precursor to atherothrombosis, ischemic heart disease, and leading cause of death in the industrialized world. During atherogenesis, apoptotic cell turnover in the vascular wall is counterbalanced by neighboring phagocytes with high clearance efficiency, thereby limiting cellularity and maintaining lesion integrity. However, as lesions mature, phagocytic removal of apoptotic cells (efferocytosis) becomes defective, leading to secondary necrosis, expansion of plaque necrotic cores, and susceptibility to rupture. Recent genetic causation studies in experimental rodents have implicated key molecular regulators of efferocytosis in atherosclerotic progression. These include MER tyrosine kinase (MERTK), milk fat globule-EGF factor 8 (MFGE8), and complement C1q. At the cellular level, atheromata are infiltrated by a heterogenous population of professional phagocytes, comprised of monocytes, differentiated macrophages, and CD11c(+) dendritic-like cells. Each cell type is characterized by disparate clearance efficiencies and varying activities of key phagocytic signaling molecules. It is in this context that we outline a working model whereby plaque necrosis and destabilization is jointly promoted by (1) direct inhibition of core phagocytic signaling pathways and (2) expansion of phagocyte subsets with poor clearance capacity. Towards identifying targets for promoting efficient apoptotic cell clearance and resolving inflammation in atherosclerosis and during ischemic heart disease and post myocardial infarction, this review will discuss potential in vivo suppressors of efferocytosis at each stage of clearance and how these putative interventional targets may differentially affect uptake at the level of vascular phagocyte subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.